Red Cell: Improving patients' outcomes
Special Interest Group 3 of 3
Day: Wednesday | Time: 15:00 - 16:30
Session Coordinators:
Lesley Bruce & Vanja Crew
Speakers:
Enhancement of red blood cell transfusion compatibility using CRISPR-mediated erythroblast gene editing
Tim Satchwell, School of Biochemistry, University of Bristol
Potential predictive biomarkers for transfusion in thalassaemia: a proteomic approach
Janejira Kittivorapart, Bristol Institute for Transfusion Sciences, NHSBT Bristol; School of Biochemistry, University of Bristol
Redjuvenate – validation study for the trial
Peter Smethurst, Component Development Laboratory, NHSBT Cambridge
Intended Audience
Biomedical scientists and trainees working in hospital transfusion departments; UK Blood Services and associated services; research scientists involved in red cell and/or basic research work; clinicians who prescribe blood components in haematology, surgery, intensive care, obstetrics and trauma settings; transfusion practitioners; anyone in the wider scientific community who is interested in the current red cell research carried out in the UK.
Learning Objectives
1) Learning about the problems associated with red cell transfusion compatibility and how they may be eleviated by CRISPR-mediated gene editing of cultured erythroblasts;
2) Introduction to transfusion in thalassaemia and the use of red cell proteomics in identifying potential biomarkers that may improve patients' transfusion regime;
3) Learning about the latest developments in the 'Redjuvenate' trial of red cell rejuvenation which is hoped to help with the transfusion associated organ injury in cardiac surgery
Brief Description
The third session of this year's Red Cell SIG, with the theme 'Improving patients' outcomes', will focus on novel research which may cause an improvement in patients' outcomes. Participants will learn about how gene editing of erythroblasts may be used to eleviate problems with transfusion compatibility, how red cell proteomics is used for identifying potential biomarkers in thalassaemia and how the 'Redjuvenate' trial of red cell rejuvenation can attenuate transfusion associated organ injury in cardiac surgery.
Session Tags
Improving Patient Outcomes
Diagnostics, Science & Technology
Education
